Cullinan Management (CGEM) Price & Analysis

Compare

226 Followers

CGEM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.44 - $18.62

Previous CloseN/A

Volume73.34K

Average Volume (3M)450.46K

Market Cap

$382.21M

Enterprise Value$180.42M

Total Cash (Recent Filing)$265.48M

Total Debt (Recent Filing)$1.52M

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Nov 06, 2025

EPS Estimate

-0.95

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.07

Shares Outstanding59,074,390

10 Day Avg. Volume584,672

30 Day Avg. Volume450,465

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.47

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-589.61

Enterprise Value/Ebitda-0.77

Forecast

1Y Price Target

$27.33

Price Target Upside312.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Product PotentialZipalertinib continues to show strong efficacy in previously treated patients, which along with its favorable tolerability profile should bode well for potential uptake in the second-line setting.

Stock ValuationPipeline programs such as zipalertinib and CLN-049 have the potential to meaningfully contribute to Cullinan’s valuation given that the stock trades slightly below cash on hand.

Trial ResultsPreliminary interim results from the cohort with uncommon non-ex20ins mutation in the ongoing Phase 2b REZILIENT2 trial support potential expansion of the TAM for zipalertinib.

Bears Say

Enrollment DelaysInitial data for CLN-978 in systemic lupus erythematosus is now expected later than previously guided due to slower enrollment.

Investor ConcernsSome investors may have greater concerns from this update and the stock could experience weakness as a result.

Regulatory RisksRisks include, but are not limited to: slower-than-expected enrollment in the Phase 3 REZILIENT3 trial; negative zipalertinib or CLN-978 efficacy data; inability to receive FDA approval; inability to advance other candidates into clinical development in a timely manner; superior data from competitor agents; and possible medium- to long-term dilution risk.

Cullinan Management News

3 ‘Strong Buy’ Biotech Stocks Top Analysts Believe Have Over 300% Upside

Wall Street analysts don’t hand out “Strong Buy” ratings lightly. When they do, it usually means they’re convinced...

8d ago

CGEM

TECX

Cullinan Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $24 price target The company...

23d ago

CGEM

Promising Trial Results and Strategic Plans Justify Buy Rating for Cullinan Management

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Cullinan Management today and set a price target...

1d ago

CGEM

Positive Buy Rating for Cullinan Management Driven by Promising Zipalertinib Trial Results in NSCLC with Uncommon EGFR Mutations

Cullinan Management, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from...

3d ago

CGEM

Promising Drug Pipeline and Strategic Collaborations Drive Buy Rating for Cullinan Management

William Blair analyst Matt Phipps has reiterated their bullish stance on CGEM stock, giving a Buy rating on...

4d ago

CGEM

Cullinan Management’s Strategic Adjustments and Pipeline Development Justify Buy Rating

Leerink Partners analyst Andrew Berens has maintained their bullish stance on CGEM stock, giving a Buy rating on...

5d ago

CGEM

Promising Potential of Cullinan Management’s CLN-978 Therapy Drives Buy Rating

Analyst Julian Harrison from BTIG reiterated a Buy rating on Cullinan Management and keeping the price target at...

8d ago

CGEM

Cullinan Management: Strategic Positioning and Growth Potential Justify Buy Rating Despite Study Delay

William Blair analyst Matt Phipps has maintained their bullish stance on CGEM stock, giving a Buy rating today....

9d ago

CGEM

Cullinan Management: Promising Growth Amid SLE Trial Delay with Strong Pipeline and Strategic Focus

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Cullinan Management, with a...

9d ago

CGEM

Cullinan Management Updates Strategic Goals and Timeline

Cullinan Management ( ($CGEM) ) has provided an announcement. Cullinan Therapeutics has updated its corporate presentation, outlining its...

9d ago

CGEM

Promising Developments in Cullinan Management’s Cancer Treatment Pipeline Drive Buy Rating

Cullinan Management (CGEM) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns. Robert Burns...

23d ago

CGEM

Cullinan has positive read from Novartis data, says Clear Street

After Novartis (NVS) announced that both of two Phase 3 trials evaluating ianalumab in adults with active Sjogren’s...

1M ago

NVS

CGEM

Cullinan Therapeutics reports Q2 EPS ($1.07), consensus (86c)

“I am proud of the team’s strong execution throughout the first half of the year as we continue...

1M ago

CGEM

Cullinan Therapeutics management to meet virtually with Clear Street

Virtual Meeting to be held on July 30 hosted by Clear Street. Published first on TheFly – the...

2M ago

CGEM

CGEM FAQ

What was Cullinan Management’s price range in the past 12 months?

Cullinan Management lowest stock price was $6.44 and its highest was $18.62 in the past 12 months.

What is Cullinan Management’s market cap?

Cullinan Management’s market cap is $382.21M.

When is Cullinan Management’s upcoming earnings report date?

Cullinan Management’s upcoming earnings report date is Nov 06, 2025 which is in 54 days.

How were Cullinan Management’s earnings last quarter?

Cullinan Management released its earnings results on Aug 07, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.858 by -$0.212.

Is Cullinan Management overvalued?

According to Wall Street analysts Cullinan Management’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cullinan Management pay dividends?

Cullinan Management does not currently pay dividends.

What is Cullinan Management’s EPS estimate?

Cullinan Management’s EPS estimate is -0.95.

How many shares outstanding does Cullinan Management have?

Cullinan Management has 59,074,390 shares outstanding.

What happened to Cullinan Management’s price movement after its last earnings report?

Cullinan Management reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.858. Following the earnings report the stock price went down -10.787%.

Which hedge fund is a major shareholder of Cullinan Management?

Currently, no hedge funds are holding shares in CGEM

Cullinan Management Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.01%

Trailing 12-Months

Asset Growth

-23.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cullinan Management

Cullinan Oncology, Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies. The company operates in the biotechnology sector and is dedicated to advancing its portfolio of novel cancer treatments to address unmet medical needs. Cullinan leverages a rigorous scientific approach to discover and develop innovative therapies that target specific cancer pathways.

Cullinan Management (CGEM) Earnings & Revenues

Historic Earnings Reports

CGEM Stock 12 Month Forecast

Average Price Target

$27.33

▲(312.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","35":"$35","13.25":"$13.25","20.5":"$20.5","27.75":"$27.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,13.25,20.5,27.75,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.49,9.52923076923077,11.568461538461538,13.607692307692307,15.646923076923077,17.686153846153847,19.725384615384613,21.764615384615382,23.803846153846152,25.84307692307692,27.88230769230769,29.92153846153846,31.96076923076923,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.49,9.016153846153847,10.542307692307691,12.068461538461538,13.594615384615384,15.12076923076923,16.646923076923073,18.17307692307692,19.699230769230766,21.225384615384613,22.75153846153846,24.277692307692305,25.803846153846152,{"y":27.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.49,8.606153846153846,9.722307692307693,10.838461538461537,11.954615384615384,13.07076923076923,14.186923076923076,15.303076923076922,16.41923076923077,17.535384615384615,18.65153846153846,19.767692307692307,20.88384615384615,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.76,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.18,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >